This is perhaps the most exciting new hair loss treatment in development. Currently in Phase 3 clinical trials, pyrilutamide (KX-826) is very close to becoming the first FDA-approved treatment for androgenetic alopecia in decades.
HMI-115 is a human monoclonal antibody drug being developed by Chinese company Hope Medicine for the treatment of androgenetic alopecia (male and female pattern hair loss).
In November 2021, Hope Medicine received FDA approval to start Phase 2 clinical trials of HMI-115 for androgenetic alopecia. In 2020, the FDA also approved Phase 2 trials of the same drug for endometriosis. Phase 2 clinical trials of HMI-115 for hair loss are due to begin in the USA soon.
In Australia, Phase 1 trials are currently underway. The trial is due to last 6 months, with 20 participants receiving injections every 2 weeks (12 injections total).
Since November, one of the participants in this Phase 1 Australian trial – a 37 year old man with the Reddit username moeman32 – has been posting some details of his experience to Reddit.
Antihistamines are commonly used to alleviate the symptoms of allergies. If you’ve ever suffered from hay fever, you’ll know these drugs can be effective at reducing itchiness and sneezing. But antihistamines may also reduce PGD2 levels and inflammation – both of which are linked to hair loss. This has led some hair loss sufferers to try out antihistamines in an attempt to beat baldness. One antihistamine – cetirizine – is particularly popular online for this purpose. But does it really work for hair loss?
Have you ever noticed how bald men’s scalps often look shiny? How the skin appears harder and more tight compared to skin elsewhere on the body? It’s not a coincidence. In fact, these characteristics provide valuable insights into the causes of pattern hair loss. Most importantly, though, they could provide the key to reversing androgenetic alopecia and regrowing a full head of hair.
Like many medical discoveries, this one was made by accident. JAK inhibitors – a class of drugs used to treat conditions such as bone marrow cancer and rheumatoid arthritis – have been hailed as a miracle cure for hair loss. However, the truth is a little more complicated than headlines would suggest. Nevertheless, these drugs have great potential to help understand and even cure many forms of hair loss.
If you haven’t heard about it yet, CB0301 (brand name Breezula) is a topical anti-androgen that is being trialled for hair loss. It’s just finished phase 2 dose-ranging testing and shows promise. So does it work? When will it be available? Let’s take a look at this exciting future hair loss treatment.
It seems like every week there’s a new ‘breakthrough’ baldness cure. And while the reality often seems to fall short of the headlines, each discovery takes us a step closer to beating baldness. The most recent such discovery is the role of tregs in hair loss. Without these anti-inflammatory immune cells, new hair cannot be formed. This has led scientists to speculate that defective tregs may be the cause of alopecia areata, and raises the possibility of new treatments for other forms of hair loss too.
When will hair loss be cured? It’s a question of significant interest to many men and women experiencing thinning hair and baldness. At least on the face of it, though, not much progress has been made in the last few decades. But does the future hold more promise? Let’s take a look at what’s on the horizon.
Recent advances in the understanding of male pattern hair loss mean we’re closer than ever to a cure. But there’s a lot of information out there, and it’s sometimes a matter of connecting the dots and seeing the links. In this article, we’ll look at two related hair loss therapies and the common links between them.
There are plenty of exciting hair loss treatments in the pipeline. One of the most promising of these is Setipiprant, a drug that should tackle alopecia from a completely new angle. Setipiprant is currently in clinical trials and the science behind this drug is pretty compelling – perhaps this is why biopharmaceutical company Kythera snapped up the rights to it last year. So what’s the latest? Will it be a future hair loss cure, or just another disappointment? Continue reading Latest on Setipiprant: Future Hair Loss Treatment in Development